NSI 189

Drug Profile

NSI 189

Alternative Names: NSI-189; NSI-189 phosphate

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neuralstem
  • Developer Neuralstem; University of California, San Diego
  • Class Antidepressants; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Preclinical Alzheimer's disease; Angelman syndrome; Brain injuries; Cognition disorders; Diabetic neuropathies; Neurodegenerative disorders; Post-traumatic stress disorders; Stroke

Most Recent Events

  • 25 Jul 2017 The primary endpoint was not met in a phase II trial in Major Depressive Disorder
  • 28 Feb 2017 Pharmacodynamics data from a preclinical trial in Stroke released by Neuralstem
  • 22 Feb 2017 Neuralstem has patent protection for NSI 189 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top